>

NanoSyrinx in Parliament

Our Founder and CEO, Joe Healey, was invited by the Parliamentary and Scientific Committee (P&SC – https://www.scienceinparliament.org.uk/) to discuss the future and potential of Synthetic Biology for the UK and for human health.

The UK has a stated (and laudable) ambition to become a “Scientific Superpower”, and Synthetic Biology is intimately tied to that vision. It was a cornerstone of the industrial strategy under previous leadership, and is still very much at the forefront of current science policy thinking.

The panel, was organised by SynBioBeta (the largest synthetic biology community and advocacy group) and Bit.Bio (a UK ‘cell programming’ company) with the P&SC. Whilst the focus of the discussion was particularly what Synthetic Biology could offer for human health, a wide range of topics were covered including synbio for sustainability and Net Zero, as well as a discussion about what the UK entrepreneurship ecosystem needs in order to thrive.

 

The panel was chaired by Stephen Metcalfe MP (South Basildon and East Thurrock), and the speakers included (pictured left to right above):

  • Mark Kotter, CEO of Bit.bio

  • Sara Holland, Patent attorney at Potter Clarkson specialising in synbio IP

  • Stephen Metcalfe MP, chair of the session

  • Fiona Mischel, Director of Human Health content at SynBioBeta

  • Joe Healey, Founder and CEO of NanoSyrinx

Read more news

Meet our science and scientists at SITC and EORTC

Members from the NanoSyrinx team will be on the road over the coming weeks presenting exciting data from our internal developments and recent collaborations. If you’d like to learn more about our science and meet some of the talented folks responsible for it, come along to the sessions below. A copy of the poster can […]

Read more
Dr Edwin Moses, Chairman NanoSyrinx

NanoSyrinx closes £10 million GBP financing and appoints Dr. Edwin Moses as Chairman

Round co-led by BGF, Octopus Ventures and M Ventures, with support from new corporate investor, Eli Lilly and Company, and existing investors, IQ Capital and Meltwind Appointment of Edwin Moses as Chairman to support the leadership team in maximising the value of the technology platform Novel “nanosyringe” platform can deliver complex biologic payloads selectively and […]

Read more

NanoSyrinx highlighted in Cell Trends

Our CEO Joe Healey was recently invited to write a piece for Cell Trends’ “Industry Highlights”, which is now available online here. These articles offer short reads about up and coming companies and technologies that are making waves in the industry. NanoSyrinx is delighted to have had the opportunity to tell our story. The article […]

Read more